FindTrial
Sign In

Prediction of Response to Adalimumab or Tocilizumab in Rheumatoid Arthritis Based on Multi-Omics and Machine Learning: A Real-World Multicenter Study

Prediction of Response to Adalimumab or Tocilizumab in Rheumatoid Arthritis Based on Multi-Omics Data and Machine Learning: A Real-World Multicenter Clinical Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500102117
Enrollment
Unknown
Registered
2025-05-08
Start date
2025-05-08
Completion date
Unknown
Last updated
2025-05-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rheumatoid Arthritis

Interventions

Observation group:None

Sponsors

Dazhou Central Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Sign the informed consent form and be aged =18 years; Meet the 2010 ACR/EULAR classification criteria for rheumatoid arthritis; Currently using stable doses of disease-modifying anti-rheumatic drugs (DMARDs) or corticosteroids (=10 mg/day of prednisone or equivalent dose); Be initiating treatment with Adalimumab or Tocilizumab for the first time, with no prior exposure to other biologic agents.

Exclusion criteria

Exclusion criteria: Presence of other autoimmune diseases, infectious diseases, or a history of malignant tumors; Received treatment with other biologic agents or targeted small molecule drugs within the past 3 months; Pregnant or breastfeeding women, or patients unable to complete follow-up.

Design outcomes

Primary

MeasureTime frame
Multi-omics data;Clinical data;—

Countries

China

Contacts

Public ContactFanxin Zeng

Dazhou Central Hospital

fanxinly@163.com+86 135 1831 3916

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026